End stage of renal disease. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Intervention group: Patients in the isoflavone group receive, for 8 weeks, two tablets of Soyagol (Goldaru Company) per day, each containing 50 mg of soy isoflavone. Intervention 2: Co
Sponsors
National Nutrition and Food Technology Research Institute
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Continuous Ambulatory Peritoneal Dialysis for 6 months or more Body mass index below 35
Exclusion criteria
Exclusion criteria: infections; inflammatory diseases liver diseases past medical history of cancer receiving glucocorticoid and anti-inflammatory drugs receiving isoflavone supplements Constant consumption of soy or foods containing soy in the diet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum concentrations of glucose. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Enzymatic method.;Serum concentrations of fructoseamine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of carboxymethyl lysine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of pentosidine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Systolic blood pressure. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: mercury sphygmomanometer.;Diastolic blood pressure. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: mercury sphygmomanometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hadi Tabibi
Faculty of Nutrition and Food Technology, Shahid Beheshti medical university
Outcome results
None listed